UK Markets closed

Clinigen Group Plc (CLIN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
925.00+1.00 (+0.11%)
At close: 05:15PM BST

Clinigen Group Plc

Pitcairn House
Crown Square Centrum 100
Burton Upon Trent DE14 2WW
United Kingdom
44 1283 495 010

IndustryMedical Distribution
Full-time employees1,069

Key executives

NameTitlePayExercisedYear born
Mr. Shaun Edward ChiltonCEO & Exec. Director662kN/A1968
Richard PalingInterim Chief Financial Officer & Group Financial ControllerN/AN/AN/A
Mr. Sam HerbertChief Operating OfficerN/AN/AN/A
Matt ParrishHead of Investor RelationsN/AN/AN/A
Ms. Amanda MillerGen. Counsel & Company Sec.N/AN/AN/A
Mr. David BryantDirector of Corp. Devel.N/AN/AN/A
Rob FoxVP of Investor Relations & Corp. Devel.N/AN/AN/A
Jessica ArcherGlobal HR DirectorN/AN/AN/A
Mr. Mark CorbettManaging Director of Global Access DivisionN/AN/AN/A
Mr. Johannes WillemseChief Commercial OfficerN/AN/A1968
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Corporate governance

Clinigen Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.